David Arterburn1, Robert Wellman1, Ana Emiliano2, Steven R Smith3, Andrew O Odegaard4, Sameer Murali5, Neely Williams6, Karen J Coleman5, Anita Courcoulas7, R Yates Coley1, Jane Anau1, Roy Pardee1, Sengwee Toh8, Cheri Janning9, Andrea Cook1, Jessica Sturtevant8, Casie Horgan8, Kathleen M McTigue7. 1. Kaiser Permanente Washington Health Research Institute, Seattle, Washington (D.A., R.W., R.Y.C., J.A., R.P., A.C.). 2. Rockefeller University, New York, New York (A.E.). 3. The Translational Research Institute for Metabolism and Diabetes, Florida Hospital, Orlando, Florida (S.R.S.). 4. University of California, Irvine, School of Medicine, Irvine, California (A.O.O.). 5. Kaiser Permanente Southern California, Pasadena, California (S.M., K.J.C.). 6. Community Partners' Network, Nashville, Tennessee (N.W.). 7. University of Pittsburgh, Pittsburgh, Pennsylvania (A.C., K.M.M.). 8. Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (S.T., J.S., C.H.). 9. Duke Clinical & Translational Science Institute, Durham, North Carolina (C.J.).
Abstract
Background: There has been a dramatic shift in use of bariatric procedures, but little is known about their long-term comparative effectiveness. Objective: To compare weight loss and safety among bariatric procedures. Design: Retrospective observational cohort study, January 2005 to September 2015. (ClinicalTrials.gov: NCT02741674). Setting: 41 health systems in the National Patient-Centered Clinical Research Network. Participants: 65 093 patients aged 20 to 79 years with body mass index (BMI) of 35 kg/m2 or greater who had bariatric procedures. Intervention: 32 208 Roux-en-Y gastric bypass (RYGB), 29 693 sleeve gastrectomy (SG), and 3192 adjustable gastric banding (AGB) procedures. Measurements: Estimated percent total weight loss (TWL) at 1, 3, and 5 years; 30-day rates of major adverse events. Results: Total numbers of eligible patients with weight measures at 1, 3, and 5 years were 44 978 (84%), 20 783 (68%), and 7159 (69%), respectively. Thirty-day rates of major adverse events were 5.0% for RYGB, 2.6% for SG, and 2.9% for AGB. One-year mean TWLs were 31.2% (95% CI, 31.1% to 31.3%) for RYGB, 25.2% (CI, 25.1% to 25.4%) for SG, and 13.7% (CI, 13.3% to 14.0%) for AGB. At 1 year, RYGB patients lost 5.9 (CI, 5.8 to 6.1) percentage points more weight than SG patients and 17.7 (CI, 17.3 to 18.1) percentage points more than AGB patients, and SG patients lost 12.0 (CI, 11.6 to 12.5) percentage points more than AGB patients. Five-year mean TWLs were 25.5% (CI, 25.1% to 25.9%) for RYGB, 18.8% (CI, 18.0% to 19.6%) for SG, and 11.7% (CI, 10.2% to 13.1%) for AGB. Patients with diabetes, those with BMI less than 50 kg/m2, those aged 65 years or older, African American patients, and Hispanic patients lost less weight than patients without those characteristics. Limitation: Potential unobserved confounding due to nonrandomized design; electronic health record databases had missing outcome data. Conclusion: Adults lost more weight with RYGB than with SG or AGB at 1, 3, and 5 years; however, RYGB had the highest 30-day rate of major adverse events. Small subgroup differences in weight loss outcomes were observed. Primary Funding Source: Patient-Centered Outcomes Research Institute.
Background: There has been a dramatic shift in use of bariatric procedures, but little is known about their long-term comparative effectiveness. Objective: To compare weight loss and safety among bariatric procedures. Design: Retrospective observational cohort study, January 2005 to September 2015. (ClinicalTrials.gov: NCT02741674). Setting: 41 health systems in the National Patient-Centered Clinical Research Network. Participants: 65 093 patients aged 20 to 79 years with body mass index (BMI) of 35 kg/m2 or greater who had bariatric procedures. Intervention: 32 208 Roux-en-Y gastric bypass (RYGB), 29 693 sleeve gastrectomy (SG), and 3192 adjustable gastric banding (AGB) procedures. Measurements: Estimated percent total weight loss (TWL) at 1, 3, and 5 years; 30-day rates of major adverse events. Results: Total numbers of eligible patients with weight measures at 1, 3, and 5 years were 44 978 (84%), 20 783 (68%), and 7159 (69%), respectively. Thirty-day rates of major adverse events were 5.0% for RYGB, 2.6% for SG, and 2.9% for AGB. One-year mean TWLs were 31.2% (95% CI, 31.1% to 31.3%) for RYGB, 25.2% (CI, 25.1% to 25.4%) for SG, and 13.7% (CI, 13.3% to 14.0%) for AGB. At 1 year, RYGB patients lost 5.9 (CI, 5.8 to 6.1) percentage points more weight than SG patients and 17.7 (CI, 17.3 to 18.1) percentage points more than AGBpatients, and SG patients lost 12.0 (CI, 11.6 to 12.5) percentage points more than AGBpatients. Five-year mean TWLs were 25.5% (CI, 25.1% to 25.9%) for RYGB, 18.8% (CI, 18.0% to 19.6%) for SG, and 11.7% (CI, 10.2% to 13.1%) for AGB. Patients with diabetes, those with BMI less than 50 kg/m2, those aged 65 years or older, African American patients, and Hispanic patients lost less weight than patients without those characteristics. Limitation: Potential unobserved confounding due to nonrandomized design; electronic health record databases had missing outcome data. Conclusion: Adults lost more weight with RYGB than with SG or AGB at 1, 3, and 5 years; however, RYGB had the highest 30-day rate of major adverse events. Small subgroup differences in weight loss outcomes were observed. Primary Funding Source: Patient-Centered Outcomes Research Institute.
Authors: Manuel Ferrer-Márquez; Juan José García-Díaz; Almudena Moreno-Serrano; José Miguel García-Díez; Manuel Ferrer-Ayza; Raquel Alarcón-Rodríguez; Enrique G Artero; Alberto Soriano-Maldonado Journal: Obes Surg Date: 2017-02 Impact factor: 4.129
Authors: Matthew L Maciejewski; David E Arterburn; Lynn Van Scoyoc; Valerie A Smith; William S Yancy; Hollis J Weidenbacher; Edward H Livingston; Maren K Olsen Journal: JAMA Surg Date: 2016-11-01 Impact factor: 14.766
Authors: David Arterburn; David R Flum; Emily O Westbrook; Sharon Fuller; Mary Shea; Steven N Bock; Jeffrey Landers; Katie Kowalski; Emily Turnbull; David E Cummings Journal: Surg Obes Relat Dis Date: 2013-06-04 Impact factor: 4.734
Authors: Guilherme S Mazzini; Jad Khoraki; Matthew G Browning; Bernardo M Pessoa; Luke G Wolfe; Guilherme M Campos Journal: Obes Surg Date: 2020-03 Impact factor: 4.129
Authors: Rebecca L Pearl; Thomas A Wadden; Kaylah Walton; Kelly C Allison; Jena Shaw Tronieri; Noel N Williams Journal: Surg Obes Relat Dis Date: 2019-01-25 Impact factor: 4.734
Authors: Kimberly Y Kreitinger; Macy M S Lui; Robert L Owens; Christopher N Schmickl; Eduardo Grunvald; Santiago Horgan; Janna R Raphelson; Atul Malhotra Journal: Obesity (Silver Spring) Date: 2020-11 Impact factor: 5.002
Authors: Kajsa Sjöholm; Lena M S Carlsson; Magdalena Taube; Carel W le Roux; Per-Arne Svensson; Markku Peltonen Journal: Diabetes Care Date: 2020-09-01 Impact factor: 19.112
Authors: Anita Courcoulas; R Yates Coley; Jeanne M Clark; Corrigan L McBride; Elizabeth Cirelli; Kathleen McTigue; David Arterburn; Karen J Coleman; Robert Wellman; Jane Anau; Sengwee Toh; Cheri D Janning; Andrea J Cook; Neely Williams; Jessica L Sturtevant; Casie Horgan; Ali Tavakkoli Journal: JAMA Surg Date: 2020-03-01 Impact factor: 14.766
Authors: Anita P Courcoulas; Eric Johnson; David E Arterburn; Sebastien Haneuse; Lisa J Herrinton; David P Fisher; Robert A Li; Mary Kay Theis; Liyan Liu; Brianna Taylor; Julie Cooper; Philip L Chin; Gary G Grinberg; Anirban Gupta; Shireesh Saurabh; Scott S Um; Panduranga R Yenumula; Jorge L Zelada; Karen J Coleman Journal: Ann Surg Date: 2021-08-13 Impact factor: 12.969